Breast cancer-related lymphedema (BCRL) of the upper limb is a chronic complication of breast cancer treatment that significantly impairs patient quality of life. Conventional management typically begins only after overt swelling occurs. This reactive approach delays diagnosis, relies on subjective assessment, and prioritizes volume reduction over functional recovery. Consequently, it often misses the optimal window for intervention. Recent advances in objective early-monitoring technologies, such as hyperspectral imaging and bioelectrical impedance analysis, alongside the development of precision functional lymphatic surgery, are now transforming BCRL care. This article details a novel “Precision Collaborative Management” paradigm, which integrates these diagnostic and surgical advances into a synergistic cycle where monitoring informs clinical decisions and surgical outcomes refine subsequent strategies. This paradigm establishes a continuous management pathway encompassing risk screening, early warning, precise intervention, and long-term follow-up across the entire disease continuum. Through sustained exploration in the aforementioned directions, we aim to transform BCRL management from a reactive symptom treatment to a proactive health safeguard, ultimately empowering breast cancer survivors to achieve a comprehensive and high-quality life. The paradigm facilitates a fundamental shift in BCRL clinical practice from delayed symptomatic treatment to early, function-preserving care.
Wu et al. (2026) studied this question.